Cognitive Behavioral Therapy and Chronic Pain Self-Management Within the Context of Opioid Reduction: The EMPOWER Study
NCT03445988 · Status: COMPLETED · Phase: NA · Type: INTERVENTIONAL · Enrollment: 1462
Last updated 2025-03-24
Summary
The proposed study will fill several critical gaps in evidence that are preventing patients and physicians from making informed decisions about their pain care. This project will provide patients taking opioids and physicians with the specific evidence they need to choose the most effective route to pain control, reduced pain interference, opioid reduction, and improved role function, thereby improving patient care.
The aims of this study are to (1) reduce or contain prescription opioid use while maintaining pain control and (2) compare the effectiveness of the Chronic Pain Self-Management Program (CPSMP), Cognitive Behavioral Therapy for chronic pain (pain-CBT), and no behavioral treatment within the context of patient-centered collaborative opioid tapering (Taper Only).
The acronym EMPOWER stands for Effective Management of Pain and Opioid-Free Ways to Enhance Relief.
Conditions
Interventions
- BEHAVIORAL
-
Cognitive Behavioral Therapy
A trained psychologist delivers pain-CBT to individual patients or groups of patients with chronic pain. Group treatment is delivered across 8 weekly sessions that last for 2 hours each. Pain-CBT incorporates interactive discussion, practice of relaxation training, action planning, and home exercises into each session. Pain-CBT is effective for reducing pain intensity, pain catastrophizing, depression and social impacts.
- BEHAVIORAL
-
Chronic Pain Self Management Program
The CPSMP is similar to pain-CBT in format and content but is peer-led, and is effective across pain conditions (e.g., back pain, arthritis) for improving pain and pain self-efficacy. The CPSMP consists of six weekly 2-hour group sessions in which two peer co-leaders provide patient education about pain, effective self-management, pain impacts, and other symptoms from a highly structured manual. Similar to pain-CBT, CPSMP incorporates interactive discussion, practice of relaxation training, action planning, and home exercises into each session
- OTHER
-
Taper Only
Participants allocated to 'Taper Only' will engage in a physician-guided, patient-centered opioid tapering program without additional behavioral intervention.
Sponsors & Collaborators
-
Patient-Centered Outcomes Research Institute
collaborator OTHER - lead OTHER
Principal Investigators
-
Beth Darnall, Ph.D. · Stanford University
Study Design
- Allocation
- RANDOMIZED
- Purpose
- TREATMENT
- Masking
- SINGLE
- Model
- PARALLEL
Eligibility
- Min Age
- 18 Years
- Max Age
- 85 Years
- Sex
- ALL
- Healthy Volunteers
- No
Timeline & Regulatory
- Start
- 2018-07-24
- Primary Completion
- 2023-11-06
- Completion
- 2023-11-06
Countries
- United States
Study Locations
More Related Trials
-
Open-Label, Extension Study to Evaluate the Safety of Hydrocodone Bitartrate Extended-Release Tablets
NCT01922739 ·Status: COMPLETED ·Phase: PHASE3
-
A Study to Evaluate the Effectiveness and Safety of CG5503 (Tapentadol) in the Treatment of Chronic Tumor Related Pain Compared With Placebo and Morphine
NCT00505414 ·Status: TERMINATED ·Phase: PHASE3
-
Adjunctive Mindfulness During Opioid Tapering for patientS With Chronic Pain (The AMOS Study)
NCT06268522 ·Status: COMPLETED ·Phase: NA
-
Slow Opioid Tapering Pilot Study of Patients Using Chronic Opioid Therapy
NCT05297396 ·Status: COMPLETED ·Phase: NA
-
An Open-label Extension Study With Flexible Dosing of Extended-release (ER) Tapentadol (CG5503) to Treat Patients With Moderate to Severe Chronic Pain
NCT00487435 ·Status: COMPLETED ·Phase: PHASE3
-
Comparison of Increasing Doses of Tapentadol Versus a Combination of Tapentadol and Pregabalin
NCT01352741 ·Status: COMPLETED ·Phase: PHASE4
-
Developing and Pilot Testing an Opioid Tapering Protocol
NCT04257695 ·Status: COMPLETED ·Phase: NA
-
Trial Applying Policy to Eliminate or Reduce Inappropriate Narcotics in the General-population
NCT03400384 ·Status: COMPLETED ·Phase: NA
-
Efficacy and Safety of Hydrocodone Bitartrate Extended-Release Tablets for Moderate to Severe Chronic Low Back Pain
NCT01789970 ·Status: COMPLETED ·Phase: PHASE3
-
Efficacy and Safety Study of CB-5945 for the Treatment of Opioid-Induced Constipation
NCT01901328 ·Status: TERMINATED ·Phase: PHASE3
-
A Study to Evaluate the Effectiveness and Safety of Tapentadol(CG5503) in the Treatment of Acute Pain After Hip Replacement Surgery Compared With Oxycodone and Placebo Followed by a Voluntary Open-Label Extension For Safety
NCT00364533 ·Status: TERMINATED ·Phase: PHASE3
-
Phase 3 Study of Hydrocodone Bitartrate Controlled-release Capsules in Subjects With Chronic Low Back Pain
NCT01081912 ·Status: COMPLETED ·Phase: PHASE3
-
HOnest Placebos With Explanations: Evaluating Open-Label Placebos for Chronic Pain
NCT06931158 ·Status: RECRUITING ·Phase: NA
-
A Study to Evaluate 90-Day Safety of Tapentadol(CG5503) Immediate Release (IR) or Oxycodone Immediate Release in Patients With Chronic Pain
NCT00364546 ·Status: COMPLETED ·Phase: PHASE3
-
Evolution of Analgesic Tolerance With Opioids
NCT00275249 ·Status: COMPLETED ·Phase: NA
-
Efficacy and Safety of Hydrocodone Bitartrate (HYD) in Subjects With Moderate to Severe Chronic Low Back Pain
NCT01452529 ·Status: COMPLETED ·Phase: PHASE3
-
Tapentadol Versus Oxycodone - a Mechanism-based Treatment Approach in Neuropathic Pain
NCT01458015 ·Status: TERMINATED ·Phase: PHASE4
-
Efficacy and Safety Study of CB-5945 for the Treatment of Opioid-Induced Constipation
NCT01901302 ·Status: TERMINATED ·Phase: PHASE3
-
A Study to Assess the Abuse Potential of Hydrocodone Extended-Release Tablet in Recreational Opioid Users
NCT01596673 ·Status: COMPLETED ·Phase: PHASE1
-
Long-Term Study of Hydrocodone Bitartrate Controlled-release Capsules in Subjects With Chronic Pain
NCT01115569 ·Status: COMPLETED ·Phase: PHASE3
-
Pharmacokinetic Characterization of Two Novel CG5503 Tablet Formulations in Healthy Volunteers
NCT03956134 ·Status: COMPLETED ·Phase: PHASE1
-
Evaluation of Effectiveness and Tolerability of Tapentadol Hydrochloride in Subjects With Severe Chronic Low Back Pain Taking Either WHO Step I or Step II Analgesics or no Regular Analgesics
NCT00983385 ·Status: COMPLETED ·Phase: PHASE3
-
taPentadol cLinical prAcTice IN belgiUM
NCT03814993 ·Status: COMPLETED
-
A Study to Evaluate Long-Term Safety of Multiple Doses of Tapentadol (CG5503) Prolonged-Release (PR) and Oxycodone Controlled-Release (CR) in Patients With Chronic Pain
NCT00361504 ·Status: COMPLETED ·Phase: PHASE3
-
Effect of LASER Photobiomodulation Therapy on Chronic Pain and Opioid Weaning
NCT03437967 ·Status: TERMINATED ·Phase: NA